XML 21 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 28, 2018
Sep. 29, 2017
Statement of Cash Flows [Abstract]    
Net income $ 329,981 $ 115,738
Adjustments to reconcile net income (loss) to net cash provided by operating activities:    
Depreciation and amortization 2,876 842
Stock-based compensation expense 28,330 15,029
401(k) matching contributions made in common stock 3,232 1,373
Loss on extinguishment of debt 0 6,239
Amortization of debt discounts and debt issuance costs 0 182
Interest paid in kind 0 (11,825)
Gain on other equity investments (209) (2,980)
Other (1,423) 157
Changes in assets and liabilities:    
Trade and other receivables (15,645) (49,241)
Inventory, net (3,776) (2,468)
Unbilled collaboration revenue (32,673) 0
Prepaid expenses and other current assets (3,529) (2,530)
Operating lease right-of-use assets 2,732 0
Other long-term assets (542) 689
Accounts payable (1,248) (577)
Accrued compensation and benefits 6,210 (420)
Accrued clinical trial liabilities (891) 2,050
Rebates and fees due customers 4,124 1,723
Accrued collaboration liabilities (577) 7,091
Deferred revenue (1,548) 20,710
Long-term portion of lease liabilities (974) 0
Other current and long-term liabilities (3,321) 10,476
Net cash provided by operating activities 311,129 112,258
Cash flows from investing activities:    
Purchases of Property and equipment and other, net (30,403) (3,449)
Proceeds from sale of property and equipment 308 14
Purchases of investments (368,304) (248,046)
Proceeds from maturities of investments 231,204 266,335
Proceeds from sale of investments 11,935 37,294
Proceeds from other equity investments 209 2,980
Net cash provided by (used in) investing activities (155,051) 55,128
Cash flows from financing activities:    
Repayment of convertible notes and term loan payable 0 (185,788)
Proceeds from exercise of stock options 10,390 16,532
Proceeds from employee stock purchase plan 3,650 3,053
Taxes paid related to net share settlement of equity awards (3,205) (3,012)
Net cash used in financing activities 10,835 (169,215)
Net increase (decrease) in cash, cash equivalents and restricted cash 166,913 (1,829)
Cash, cash equivalents and restricted cash at beginning of period 188,314 155,836
Cash, cash equivalents and restricted cash at end of period 355,227 154,007
Supplemental cash flow disclosure - non-cash investing and financing activity:    
Property and equipment deemed to have been acquired under build-to-suit lease 0 14,530
Right-of-use assets obtained in exchange for lease obligations [1] 17,180 0
Unpaid liabilities incurred to acquire Property and equipment $ 1,281 $ 245
[1] Amounts for the nine months ended September 30, 2018 include the transition adjustment for the adoption of Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) (“Topic 842”).